Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Mika Mustonen"'
Autor:
Katriina J. Jalkanen, Erika Alanne, Sanna Iivanainen, Okko-Sakari Kääriäinen, Minna Tanner, Annika Auranen, Jussi Koivunen, Timo K. Nykopp, Pia Vihinen, Mika Mustonen
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Externí odkaz:
https://doaj.org/article/405f70b94e7a4bcebdd4fc67935446b4
Publikováno v:
Metsätieteen aikakauskirja, Vol 2017 (2017)
Externí odkaz:
https://doaj.org/article/56ffb2d4f17d4c4fa20be65235e02d84
Autor:
Lars Högbom, Dalia Abbas, Kęstutis Armolaitis, Endijs Baders, Martyn Futter, Aris Jansons, Kalev Jõgiste, Andis Lazdins, Diana Lukminė, Mika Mustonen, Knut Øistad, Anneli Poska, Pasi Rautio, Johan Svensson, Floor Vodde, Iveta Varnagirytė-Kabašinskienė, Jan Weslien, Lars Wilhelmsson, Daiga Zute
Publikováno v:
Sustainability, Vol 13, Iss 5643, p 5643 (2021)
Forests are the dominant land cover in Nordic–Baltic countries, and forestry, the management of forests for improved ecosystem-service (ES) delivery, is an important contributor to sustainability. Forests and forestry support multiple United Nation
Autor:
Rebecca Kristeleit, Antoine Italiano, Hendrik Tobias Arkenau, Mika Mustonen, Pasi Hakulinen, Analia Azaro, Giuseppe Curigliano, Petri Bono, Jordi Rodon, Tarja Ikonen, Ulrik Lassen, Chris Garratt, Christophe Massard, Katriina Peltola
Publikováno v:
Scientia
ESMO Open, Vol 5, Iss 6 (2020)
ESMO Open
Bono, P, Massard, C, Peltola, K J, Azaro, A, Italiano, A, Kristeleit, R S, Curigliano, G, Lassen, U, Arkenau, H T, Hakulinen, P, Garratt, C, Ikonen, T, Mustonen, M V J & Rodon, J A 2020, ' Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours ', ESMO Open, vol. 5, no. 6, e001081 . https://doi.org/10.1136/esmoopen-2020-001081
ESMO Open, Vol 5, Iss 6 (2020)
ESMO Open
Bono, P, Massard, C, Peltola, K J, Azaro, A, Italiano, A, Kristeleit, R S, Curigliano, G, Lassen, U, Arkenau, H T, Hakulinen, P, Garratt, C, Ikonen, T, Mustonen, M V J & Rodon, J A 2020, ' Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours ', ESMO Open, vol. 5, no. 6, e001081 . https://doi.org/10.1136/esmoopen-2020-001081
Estudi d'escalada de dosis; Fase I; Tumors sòlids Estudio de escalada de dosis; Fase I; Tumores sólidos Dose escalation study; Phase I; Solid tumours Background Genetic alterations in fibroblast growth factor receptor (FGFR) and vascular endothelia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::164c723e495210e45a1eff22d3221919
https://hdl.handle.net/11351/6423
https://hdl.handle.net/11351/6423
Autor:
Matti Poutanen, Riikka Huhtaniemi, Sari Mäkelä, Matias Knuuttila, Claes Ohlsson, Riikka Oksala, Laura L. Elo, Pekka Kallio, Arfa Mehmood, Eija Aho, Petra Sipilä, Asta Laiho, Tero Aittokallio, Daniel Nicorici, Teemu D. Laajala, Mika Mustonen
Publikováno v:
American Journal of Pathology. 188(12):2890-2901
The role of adrenal androgens as drivers for castration-resistant prostate cancer (CRPC) growth in humans is generally accepted; however, the value of preclinical mouse models of CRPC is debatable, because mouse adrenals do not produce steroids activ
Autor:
Lars Edenbrandt, R. Jones, Karim Fizazi, Mika Mustonen, Christophe Massard, Elin Trägårdh, Leena Mattila, Per Wollmer, Eva Bondesson, Mariana Reza, Anders Bjartell, John Aspegren
Publikováno v:
European Urology Focus. 2:547-552
Background\ud \ud ODM-201, a new-generation androgen receptor inhibitor, has shown clinical efficacy in prostate cancer (PCa). Quantitative methods are needed to accurately assess changes in bone as a measurement of treatment response. The Bone Scan
Autor:
Meri Ramela, Reetta Riikonen, Riikka Oksala, Kati Rasanen, Mika Mustonen, Gerd Wohlfahrt, Mari Karimaa, Pirjo Vehmaan-Kreula, Petteri Rummakko
Publikováno v:
Endocrine Abstracts.
Autor:
Riikka Oksala, Reetta Riikonen, Kati Rasanen, Mari Karimaa, Pirjo Vehmaan-Kreula, Gerd Wohlfahrt, Petteri Rummakko, Meri Ramela, Mika Mustonen
Publikováno v:
Journal of the Endocrine Society
Background: Prostate cancer is a major global challenge due to the increasing number of aging population and frequency of diagnosis. During the past decade new treatments have been targeted to the androgen signaling axis either by inhibiting the bind
Autor:
Mika Mustonen, Teuvo L.J. Tammela, Christophe Massard, Petri Bono, John Aspegren, Karim Fizazi, Neal D. Shore
Background: ODM-201, a new androgen receptor antagonist for treatment of metastatic castration-resistant prostate cancer (mCRPC), demonstrated antitumour activity and acceptable tolerability in phase 1/2 trials. Objective: To determine the antitumour
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a6913e4ccf93c8518a0ad7f2f4947c1
http://hdl.handle.net/10138/299672
http://hdl.handle.net/10138/299672
Autor:
Heikki Joensuu, Vesa Kataja, Petri Bono, Nicholas D. James, Christophe Massard, Teuvo L.J. Tammela, John Aspegren, Mika Mustonen, Karim Fizazi
Background: Patients with castration-resistant prostate cancer (CRPC) had extended responses to the androgen receptor antagonist ODM-201, in phase 1/2 studies. Objective: To evaluate the safety and antitumour activity of prolonged ODM-201 treatment i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2f31ead530fe5f96bb2446347ca7978
https://trepo.tuni.fi/handle/10024/103403
https://trepo.tuni.fi/handle/10024/103403